|
ATF3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.182150E-04 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.236000E-04 |
| Normal-vs-Stage2 |
6.005400E-04 |
| Normal-vs-Stage3 |
3.05290000002234E-06 |
| Normal-vs-Stage4 |
7.97439999999927E-05 |
| Stage1-vs-Stage2 |
4.835600E-01 |
| Stage1-vs-Stage3 |
5.340000E-03 |
| Stage1-vs-Stage4 |
1.370250E-01 |
| Stage2-vs-Stage3 |
4.235200E-01 |
| Stage2-vs-Stage4 |
6.782600E-01 |
| Stage3-vs-Stage4 |
7.201200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.35110000000161E-05 |
| Normal-vs-AfricanAmerican |
2.24909999999579E-05 |
| Normal-vs-Asian |
7.961500E-04 |
| Caucasian-vs-AfricanAmerican |
6.743800E-02 |
| Caucasian-vs-Asian |
5.666400E-01 |
| AfricanAmerican-vs-Asian |
5.768000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.93640000004203E-06 |
| Normal-vs-Female |
3.84949999999717E-05 |
| Male-vs-Female |
5.679900E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.895300E-03 |
| Normal-vs-Age(41-60Yrs) |
5.7313999999975E-05 |
| Normal-vs-Age(61-80Yrs) |
1.48830000001876E-06 |
| Normal-vs-Age(81-100Yrs) |
1.191610E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.231800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.778700E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.646200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.778350E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.119000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.676400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.620340E-02 |
| Classical-VS-Follicular |
6.591900E-02 |
| Classical-VS-Other |
8.574400E-01 |
| Classical-VS-Normal |
5.630500E-04 |
| Tall-VS-Follicular |
7.502400E-01 |
| Tall-VS-Other |
3.659600E-01 |
| Tall-VS-Normal |
4.97570000002057E-06 |
| Follicular-VS-Other |
6.497400E-01 |
| Follicular-VS-Normal |
2.39829999999497E-05 |
| Other-VS-Normal |
1.175380E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.91350999999562E-05 |
| Normal-vs-N1 |
2.19559999999897E-05 |
| N0-vs-N1 |
9.551200E-01 |
|
|
